BenevolentAI is a private company building in biotechnology/ai, founded in 2014. Its most recent disclosed valuation is $2B. Its shares do not trade on a public exchange.
1 valuation. The latest, $2B pre-money, was set by the Series C in Apr 2018.
TemasekLEADEExisting investorsLEADMMultiple institutional investorsTemasekExisting investorsBenevolentAI, listed on Euronext Amsterdam under the ticker BAI, is a leader in applying advanced AI to accelerate biopharma drug discovery. Its pipeline products include BEN-8744 for ulcerative colitis, BEN-28010 for glioblastoma multiforme, and BEN-34712 for Amyotrophic Lateral Sclerosis, and its platform enables scientists to design and develop new treatments for patients using a large amount of extracted and deduced biomedical information; the company also offers Qor, an always-on strategic function for biopharma decision makers and life science consultancies.
BenevolentAI was founded in 2013, and the company operates in the UK and the US, headquartered in London, England.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds BenevolentAI.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. BenevolentAI availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — BenevolentAI included.
No. BenevolentAI is a private company; its shares do not trade on a public exchange.
The last valuation is $2B.
Lead investors for each round are in the funding timeline.
The closest biotechnology/ai peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
